PROSPECTS OF NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH STAGE III A NON-SMALL CELL LUNG CANCER AS A METHOD OF IMPROVING SURVIVAL.

Objective: The aim: To study the survival rate and count the number of complications in groups with NCRT, NCT and NCT + adjuvant radiotherapy.

Patients And Methods: Materials and methods: The studied patients were divided into three groups with a total number of 304 people, Patients who received neoadjuvant chemotherapy-149 people, who received neoadjuvant chemotherapy and adjuvant radiation therapy-90 people. Neoadjuvant chemoradiotherapy was performed in accordance with Cisplatin/Docetaxel or Carboplatin/Paclitaxel 4 Mg and simultaneous radiation therapy with a total radiation dose 30 gray with a single dose of 2 Mg.

CORRELATION OF RELAPSE-FREE SURVIVAL WITH NEOADJUVANT TREATMENT IN PATIENTS WITH STAGE IIIA NON-SMALL CELL LUNG CANCER.

Objective: The aim: The aim of this study was to investigate disease-free and overall survival in patients with stage IIII A NSCLC after neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, and neoadjuvant chemotherapy.

Patients And Methods: Materials and methods: For the study, 3 groups of 65 people were taken. All patients underwent radical surgery in the form of lobectomy, bilobectomy or pneumonectomy.

[About the impact of the dendritic cell autovaccine on the results of treatment of non-small-cell lung cancer patients].

In thoracic department of the National Cancer Institute studied the effectiveness of dendritic cell autovaccine in the postoperative period in non-small-cell lung cancer patients. The results, showing good tolerance dendritic cell autovaccine. Shows the formation of the expressed antigen immune response after repeated injections dendritic cell autovaccine, as manifested after 4 revaccination.